Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.

Although the triple combination showed a trend toward a lower SBP than the control treatment, it was not statistically significant (MD = −1.23 mmHg; 95% CI = −4.83 to 2.38; P fixed-effects model = 0.50; I 2 = 0%, P heterogeneity = 0.65) ( Fig 9 ).

also in 53,322 other papers